Siobhan Cross

Dr. Siobhan Cross

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
NVNicola C. Venn
Nicola C. Venn
LHLibby Huang
Libby Huang
LHLenka Hovorková
Lenka Hovorková
WMWalter Muskovic
Walter Muskovic
MWMarie Wong
Marie Wong
RSRosemary Sutton
Rosemary Sutton
Background: ABL-class fusions including NUP214-ABL1 and EBF1-PDGFRB occur in high risk acute lymphoblastic leukaemia (ALL) with gene expression patterns similar to BCR-ABL-positive ALL. Our aim was to evaluate new DNA-based measurable residual disease (MRD) tests detecting these fusions and IKZF1-deletions in comparison with conventional immunoglobulin/T-cell receptor (Ig/TCR) markers. Methods: Precise genomic breakpoints were defined from targeted or whole genome next generation sequencing for ABL-fusions and BCR-ABL1. Quantitative PCR assays were designed and used to re-measure MRD in remission bone marrow samples previously tested using Ig/TCR markers. All MRD testing complied with EuroMRD guidelines. Results: ABL-class patients had 46% 5year event-free survival and 79% 5year overall survival. All had sensitive fusion tests giving high concordance between Ig/TCR and ABL-class fusion results (21 patients, n = 257 samples, r2 = 0.9786, P < 0.0001) and Ig/TCR and IKZF1-deletion results (9 patients, n = 143 samples, r2 = 0.9661, P < 0.0001). In contrast, in BCR-ABL1 patients, Ig/TCR and BCR-ABL1 tests were discordant in 32% (40 patients, n = 346 samples, r2 = 0.4703, P < 0.0001) and IKZF1-deletion results were closer to Ig/TCR (25 patients, n = 176, r2 = 0.8631, P < 0.0001). Conclusions: MRD monitoring based on patient-specific assays detecting gene fusions or recurrent assays for IKZF1-deletions is feasible and provides good alternatives to Ig/TCR tests to monitor MRD in ABL-class ALL.

26 September 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
DMDenitza Mironova
Denitza Mironova
CSChitra M. Saraswati
Chitra M. Saraswati
PDPeter Downie
Peter Downie
CLChow Yee Lai
Chow Yee Lai
ECEleanor Cook
Eleanor Cook
RKRishi S Kotecha
Rishi S Kotecha
Acute lymphoblastic leukaemia (ALL) in infancy, defined as ≤1 year of age at diagnosis, is rare with an incidence of 1.8 cases per 100,000 [1]. KMT2A-gene rearrangements are present in up to 80% of infants with ALL and are associated with a poor prognosis. Historically, collaborative group treatment protocols have focused on intensification of conventional chemotherapy, which can include allogeneic haematopoietic stem cell transplant (HSCT) for high-risk infants, however outcomes for KMT2Arearranged infant ALL have remained poor due to high relapse rates and treatment-related mortality [2, 3]. Given the rarity of the patient population and low survival rates, there is limited data regarding long-term outcomes in survivors of infant ALL in the context of receiving intensive therapy to achieve a cure. We conducted a multi-centre retrospective analysis of all infants diagnosed with ALL in Australia and New Zealand from 1 January 1992 to 31 December 2011 (Human Research Ethics Approval RGS0000001383). Patients were identified from the cancer registry of every paediatric cancer centre in Australia and New Zealand and standardised data were captured for each patient until 28 February 2021, including demographics, disease characteristics, treatment, outcome, a systematic capture of late effects based on the Children's Oncology Group long-term followup guidelines (version 5.0) and date of last follow-up. Event-free survival (EFS) was defined as the time from ALL diagnosis to treatment failure or relapse, all-cause mortality, or second malignancy. Overall survival (OS) was defined as the time from diagnosis to all-cause mortality. Time was censored at the last follow-up if no events were recorded. All analyses were performed using R (version 4.2.2). Over the 20-year period, 119 infants were diagnosed with ALL in Australia and New Zealand. Treatment was administered according to US or European-based infant-specific collaborative group protocols available at the time of diagnosis. Fiveyear OS was 60.5% (SE 4.5) and 5-year EFS was 47.1% (SE 4.7) (Fig. 1; Supplementary Fig. 1). EFS and OS were adversely influenced by the presence of a KMT2A-rearrangement, age <6 months, central nervous system (CNS) involvement, high presenting white blood cell count and CD10-negative immunophenotype, with male sex also an adverse prognostic factor for EFS on univariate analysis (Table 1; Supplementary Fig. 2). Cox regression analysis, with EFS as an endpoint, identified presence of a KMT2A-rearrangement, age <6 months and male

6 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CPClare Parker
Clare Parker
CSClarissa Schilstra
Clarissa Schilstra
KMKaren Mccleary
Karen Mccleary
MMMichelle Martin
Michelle Martin
TTToby Trahair
Toby Trahair
JFJoanna E. Fardell
Joanna E. Fardell
Background/Objectives: Parents of children with acute lymphoblastic leukaemia (ALL) experience emotional distress throughout their child’s treatment course. This study describes the psychological experience of Australian and New Zealand parents of children diagnosed with ALL. Methods: This prospective, longitudinal study assessed distress, anxiety, depression, anger and the need for help in parents of children with newly diagnosed ALL across eight sites between October 2018 and November 2022. Psychological symptoms were quantified using the Emotion Thermometer (ET) tool and Patient-Reported Outcome Measurement Information System (PROMIS) questionnaires. Participants were recruited within ninety days of chemotherapy commencement, with surveys distributed bimonthly thereafter. Results: One hundred and seventeen participants completed 327 survey responses spanning 0 to 62 months post-diagnosis. Parental distress peaked within the first 6 months and 40% of parents reported clinically significant symptoms across four or more domains as measured by our questionnaires. Anxiety was the most consistently elevated symptom, with over 50% of responses above the clinical cut-off. Depression and the need for help also peaked closer to diagnosis and declined over time. In contrast, anger remained stable, with 27% reporting clinically significant scores across all time points. Increased time since diagnosis was significantly associated with reductions in distress, anxiety and depression scores. Conclusions: Australian and New Zealand parents experience high levels of psychological distress within the first six months following their child’s diagnosis of ALL. A notable minority continue to report elevated distress levels over time, identifying a need for improved psychological support for family wellbeing throughout the ALL treatment trajectory.

15 February 2006 in BJU International
Verified
Journal Article
Open access
PDF file
JCJ.W.F. Catto
J.W.F. Catto
SCSiobhan Cross
Siobhan Cross
JPJ. Phillips
J. Phillips
ALA. Leiblich
A. Leiblich
HLHing Leung
Hing Leung
IRI. Rehman
I. Rehman
In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic profile of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP‐LN3, by two‐dimensional gel electrophoresis. A major protein spot (pI of 5.9 and molecular weight of 37 KDa) was seen in LNCaP cells, but not in LNCaP‐LN3 cells and was identified as Lactate dehydrogenase‐B ( LDHB ), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and Zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP‐LN3. Bisulfite modified DNA sequencing showed promoter hypermethylation in LNCaP‐LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP‐LN3 cells with 5’‐azacytidine caused re‐expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer 14/31 (45%), compared to adjacent non‐malignant or benign tissue, 2/19 (11%), ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or non‐malignant tissues, 59/ 73 (81%), compared to cancer cases, 3/53 (6%), ( P < 0.001). Absent LDHB expression was also seen in 7/7 (100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.

10 August 2026 in Journal of Paediatrics and Child Health
Verified
Journal Article
Open access
PDF file
MOMatthew J. O'COnnor
Matthew J. O'COnnor
MMMichelle Martin
Michelle Martin
STSarah M. Trinder
Sarah M. Trinder
DBDraga Barbaric
Draga Barbaric
DHDiane Hanna
Diane Hanna
SCSiobhan Cross
Siobhan Cross
Background: Asparaginase is a critical component of modern multi‐agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes. Objectives: To develop a clinical practice guideline for the use of asparaginase products in the Australasian context. Methods: This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region. Results: This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion. Conclusions: This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.